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Background
Due to an expanding knowledge about the molecular
diversity the disease Osteogenesis imperfecta (OI), for-
merly known to be a disorder of the collagen synthesis,
changed to a group of disorders with a fragile skeleton as
common symptom. Patients with OI type VI are clinically
characterized by an increased amount of osteoid and a
poor response to bisphosphonate treatment.
Patients
In two boys with signs of OI we identified the disease
causing mutation of OI VI [1]. Mutations in SERPINF1
lead to the absence of pigment epithelium derived factor
(PEDF), which is a key factor for the regulation of osteo-
clastogenesis. Without PEDF the differentiation of pre-
osteoclasts is increased and more bone will be resorbed.
Consequence
Due to the new understanding of the pathophysiology of
OI VI we decided to target the osteoclasts directly using
the Rankl-antibody Denosumab. This was the first use
of Denosumab in children.
Results
With this change of therapy we were able to reduce
bone resorption to the normal range [2].
After two years of treatment both patients show an
increase of bone mineral density of the lumbar spine with
a z-score from – 2.4 to -2.0 and -4.3 to 2.5 respectively
and an increase of projected vertebral area L2 – L4 [mm²]
from 1670 to 2152 and from 1424 to 1528. No severe side
effects were seen and the drop of serum calcium after the
subcutaneous injection could be treated by oral calcium
supplementation.
Conclusion
Clinical observation and molecular analysis lead to a new
understanding of OI VI and to a more specific therapeutic
approach. The new therapy resulted in a better therapeutic
effect and is a striking example of a fast transfer from basic
research to therapeutic use.
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